

# Supplementary Figures and tables

Characteristics		Patients (n=32)
Age (years) Median (range)		63 (48;76)
Sex		
	Male (%)	18 (56)
	Female (%)	14 (44)
Karnofsky performance score		
	60-80 (%)	11 (34)
	90-100 (%)	21 (66)
Survival time (months)		
Median (range)		12 (5;50)
Extent of surgery (%)		
	Biopsie	0
	Partial resection	0
	Complete resection	32 (100)
MGMT methylation		
	Methylated (%)	15 (47)
	Unmethylated (%)	17 (53)
IDH1 mutation		
	Wild-type (%)	31 (97)
	Mutated (%)	1 (3)



**Supplementary Table T1.**

Characteristics		Patients (n=48)
Age (years) Median (range)		62 (48;76)
Sex		
	Male (%)	26 (54)
	Female (%)	22 (46)
Karnofsky performance score		
	60-80 (%)	16 (33)
	90-100 (%)	32 (67)
Survival time (months)		
Median (range)		13 (4;53)
Extent of surgery (%)		
	Biopsie	0
	Partial resection	0
	Complete resection	48 (100)
MGMT methylation		
	Methylated (%)	23 (48)
	Unmethylated (%)	25 (52)
IDH1 mutation		
	Wild-type (%)	47 (98)
	Mutated (%)	1 (2)

## Supplementary Table T2.

Base modification detection	Methods	References
Detection of cytosine methylation in RNA	Bisulfite sequencing	Legrand et al. (2017) Genome Res. PMID: 28684555
Detection of Adenosine methylation in pri-miR	m6A Immunoprecipitation and RNA seq	Alarcon et al. (2015) Nature. PMID: 25799998
Detection of phospho-dimethylated pre-miR-145	Incorporation of radiolabelled groups	Xelmace et al. (2012) Cell. PMID: 23063121
Detection of cytosine methylation in RNA	Bisulfite sequencing	Schaefer et al. (2009) Nucleic Acids Res. PMID: 19059995
Detection of cytosine methylation in tRNA	Mass spectrometry	Goll et al. (2006) Science. PMID: 16424344
Detection of guanosine methylation in miRNA	Borohydride Reduction sequencing [BoRed-seq]	Pandolfini et al. (2019) Molecular Cell. PMID: 31031083
Detection of cytosine and adenosine methylation in miRNA	MALDI-TOF-MS	Konno et al. (2019) Nature Communications. PMID: 31467274

**Supplementary Table T3.**

**A****B**

**Figure S1. Experimentations illustrating the purity of our miRNA extractions.**










Figure S2. Calibration of HPLC for 5mC.





**Figure S3. miRNA-Bseq workflow.**

**A****B****C****D**

**Figure S4. In-cell ELISA investigating the siRNA-mediated down-regulation validation of Dicer, NSUN2, DNMT1/3A/3B and AGO1/2/3/4**



Original image from ChemiDoc (BioRad France)



**Figure S5. Original image of co-immunoprecipitation experiments.**







Figure S6. Validation of antibodies used in P-LISA experiments.


Original images from ChemiDoc (BioRad France)




		Pull down				
	His-DNMT3A	-	+	+	+	+
	GST-AGO4	+	-	+	+	+
	IgG	-	-	-	+	-
	$\alpha$ AGO4 <sup>1-164</sup>	-	-	-	-	+
WB	DNMT3A					
	AGO4					


Figure S7. Original images of pull-down experiments.

**Figure S8. Impact of siDNMT3A or AGO4 and  $\alpha$ AGO4<sup>1-164</sup> on the miR-Array profile**






**Figure S9. Dot blot illustrating the impact of the siRNA-mediated invalidation of DNMT3A and AGO4 and the use of the aAGO4<sup>1-164</sup> antibody on the global level of cytosine-methylation of miRNA.**



**Figure S10. Correlation between the level of DNMT3A/AGO4 interactions and the global level of cytosine-methylation of miRNA**




3'UTR BIM	A	U	G	U	A	A	G	U	G	U	U	G	U	U	U	G	A	A	G	G	U	A	A				
												:					:		:								
miRNA-181a (MIMAT0000256)	a	a	c	a	u	u	c	a	-	-	a	c	g	-	-	c	u	g	u	c	g	g	u	g	a	g	u
Position	1	2	3	4	5	6	7	8		9	10	11			12	13	14	15	16	17	18	19	20	21	22	23	
Cytosine-methylated											X								X								
Mutated#1			u		c		a	g																			
Mutated#2											a								a								

**Figure S11. Illustration of the he miR-181a binding site in the 3'UTR of Bim and the miRNA-181a mutant or methylated sequences.**




**Figure S12. Western blot and RT-qPCR investigating the effect of miRNA-181a-5p on BIM expression at protein and mRNA levels.**





**A****B****C**


**Figure S13. Validation of 5methylcytosine (5mC) antibodies used in our study.**




**Figure S14: The presence of 5mC in miRNA-451a abolishes its functions**







**Figure S14: The presence of 5mC in miRNA-451a abolishes its functions**



**Figure S15: The presence of 5mC in miRNA-193a-5p abolishes its functions**



**Figure S15: The presence of 5mC in miRNA-193a-5p abolishes its functions**

**A****B****C****D****Figure S16.**